AbbVie Ventures
Overview
AbbVie Ventures is the corporate venture capital arm of AbbVie that invests in novel, transformational therapeutics at discovery and pre-clinical stages . Aligning with AbbVie’s strategic focus, their investments address critical needs in oncology, immunology, neuroscience, eye care, and aesthetics . AbbVie Ventures offers its partners access to AbbVie's vast internal network of experts in all phases of drug development, from drug discovery through successful commercialization .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Quanta Therapeutics | Jun 2026 | Series D | Co-investor |
| Endlyz Therapeutics | May 2026 | Seed | Co-investor |
| Third Arc Bio | Feb 2026 | Series A Extension | Co-investor |
| DISCO Pharmaceuticals | Dec 2025 | Seed | Co-investor |
| Zag Bio | Oct 2025 | Series A | Co-investor |
Key People
Mohamad Abubakar
Co-Founder
Alina Köhler
Employee Relations Partner
Busra Polat Kahveci
Learning Partner
Catherine Lamontagne
Manager Learning Partner
Charlie Hallard
Affiliate PV Partner Compliance Specialist
Chris Phillips
Learning Partner (In Field Excellence)
James F Baum
Pharmacy Solutions Partner
Kelly Fatten
Learning Partner
Lynn Gabb
Manager, Affiliate PV Partner Compliance
Mia G.
Data Engineering Bussiness Partner UK Data Lead
Paige Passaro
Learning Partner
Paula Wurm
HR Business Excellence Partner
Rachael Dalton
Learning Partner
Rafael Tonon
Business Insights Partner
Rhonda Sharpe
Learning Partner
Sophie van Bohemen - de Vries
Learning Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
